By analyzing a cohort of 224 patients, we identified key biomarkers, including sRAGE, MCP, hsCRP, antioxidant capacity, and SOD, that can be coupled with psychiatric assessments to assess the risk of depression and delirium pre- and post-CABG. The gene discussed is SOD1; the disease is depressive disorder.